These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 33183205)

  • 1. Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.
    Sharma A; Kaliya K; Maurya SK
    Curr Top Med Chem; 2021; 21(4):307-328. PubMed ID: 33183205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
    Capasso C; Nocentini A; Supuran CT
    Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
    Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
    Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
    Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
    FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions.
    Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM
    Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in the discovery of inhibitors targeting coronavirus proteases.
    Wang H; Xue S; Yang H; Chen C
    Virol Sin; 2016 Feb; 31(1):24-30. PubMed ID: 26920707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
    Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
    Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
    Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
    J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.